Last reviewed · How we verify
Orectalip
At a glance
| Generic name | Orectalip |
|---|---|
| Also known as | Fluorouracil, Leucovorin |
| Sponsor | Sinphar Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Orectalip CI brief — competitive landscape report
- Orectalip updates RSS · CI watch RSS
- Sinphar Pharmaceutical Co., Ltd portfolio CI